Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

CPX-351+GO in Subjects 55 Years Old, or Older, With AMLTerminated
NCT03878927Phase 1Updated Mar 10, 2023
Sponsor: Weill Medical College of Cornell University
Acute Myeloid Leukemia
United States
A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic DermatitisCompleted
NCT04040192Phase 3Updated Mar 8, 2023
Sponsor: Pfizer
Atopic Dermatitis
United States, Australia, Canada, China, Israel +1 more
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)Withdrawn
NCT05259397Phase 1Updated Mar 8, 2023
Sponsor: Pfizer
Bladder Cancer
United States, Poland
Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer PatientsCompleted
NCT00128843Phase 2Updated Mar 6, 2023
Sponsor: Spanish Breast Cancer Research Group
Breast Cancer
Spain
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast CancerCompleted
NCT00129922Phase 3Updated Mar 6, 2023
Sponsor: Spanish Breast Cancer Research Group
Breast Cancer
Spain
Azithromycin for COVID-19 Treatment in Outpatients NationwideTerminated
NCT04332107Phase 3Updated Mar 2, 2023
Sponsor: Thomas M. Lietman
COVID-19 · SARS-CoV-2
United States
Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine ConditionCompleted
NCT01445067Phase 1Updated Mar 1, 2023
Sponsor: Pfizer
Migraine
United States
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19Withdrawn
NCT05545319Phase 2Updated Mar 1, 2023
Sponsor: Pfizer
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) · Coronavirus Disease 2019 (COVID-19) · Immunocompromised · Hospitalization
United States, Bulgaria
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of MigraineCompleted
NCT01430442Phase 2Updated Feb 28, 2023
Sponsor: Pfizer
Migraine · Acute Treatment of Migraine
United States
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of MigraineNo Longer Available
NCT03934086N/AUpdated Feb 23, 2023
Sponsor: Pfizer
Migraine
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid TumorsCompleted
NCT02401347Phase 2Updated Feb 21, 2023
Sponsor: Melinda Telli
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
United States
Safety and Efficacy in Adult Subjects With Acute MigrainesCompleted
NCT03237845Phase 3Updated Feb 16, 2023
Sponsor: Pfizer
Migraine, With or Without Aura
United States
Safety and Efficacy Study in Adult Subjects With Acute MigrainesCompleted
NCT03235479Phase 3Updated Feb 16, 2023
Sponsor: Pfizer
Migraine, With or Without Aura
United States
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompleted
NCT02609828Phase 3Updated Feb 16, 2023
Sponsor: Pfizer
Bone Metastasis · Cancer Pain
Argentina, Australia, Austria, Brazil, Chile +11 more
Open Label Safety Study in Acute Treatment of MigraineCompleted
NCT03266588Phase 2, Phase 3Updated Feb 16, 2023
Sponsor: Pfizer
Migraine, With or Without Aura
United States
Trial in Adult Subjects With Acute MigrainesCompleted
NCT03461757Phase 3Updated Feb 16, 2023
Sponsor: Pfizer
Migraine, With or Without Aura
United States
Clostridium Difficile Vaccine Efficacy TrialCompleted
NCT03090191Phase 3Updated Feb 13, 2023
Sponsor: Pfizer
Clostridium Difficile Infection
United States, Argentina, Australia, Belgium, Bulgaria +18 more
Growth Hormone Therapy for Muscle Regeneration in Severely Burned PatientsCompleted
NCT03038594Phase 2, Phase 3Updated Feb 13, 2023
Sponsor: The University of Texas Medical Branch, Galveston
Burns · Growth Hormone Treatment
United States
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic DermatitisCompleted
NCT03915496Phase 2Updated Feb 8, 2023
Sponsor: Pfizer
Atopic Dermatitis
United States, Canada
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced CancerCompleted
NCT00585195Phase 1Updated Feb 8, 2023
Sponsor: Pfizer
Non-Small Cell Lung Cancer ALK-positive · Non-Small Cell Lung Cancer c-Met Dependent · Non-Small Cell Lung Cancer ROS Marker Positive · Systemic Anaplastic Large-Cell Lymphoma
United States, Australia, Japan, South Korea
Non-Interventional Study Describing Direct Costs Related to Anti-coagulation TreatmentCompleted
NCT04435769N/AUpdated Feb 8, 2023
Sponsor: Pfizer
Atrial Fibrillation
Czechia
Lebanese Interhospital Pneumococcal Surveillance ProgramRecruiting
NCT00901602N/AUpdated Feb 3, 2023
Sponsor: American University of Beirut Medical Center
Pneumonia · Meningitis · Sepsis · Bacteremia
Lebanon
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese AdultsCompleted
NCT04588480Phase 4Updated Feb 1, 2023
Sponsor: BioNTech SE
SARS-CoV-2 Infection · COVID-19
Japan
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real LifeCompleted
NCT02925338N/AUpdated Jan 25, 2023
Sponsor: Pfizer
Crohn Disease · Ulcerative Colitis · Rheumatoid Arthritis · Ankylosing Spondylitis
France
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of AgeCompleted
NCT03579459Phase 3Updated Jan 19, 2023
Sponsor: Pfizer
Clostridium Difficile Associated Disease
United States

Previous page Next page